Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy

Nature Reviews Cancer

Volumn 6, Issue 3, 2006, Pages 227-239

  Overall, Christopher M ^a   Kleifeld, Oded ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; AE 941; ANTINEOPLASTIC AGENT; BATIMASTAT; BORTEZOMIB; CGS 27023A; CIPEMASTAT; COMPLEMENTARY DNA; CYCLOOXYGENASE 2 INHIBITOR; GELATINASE A; GELATINASE B; ILOMASTAT; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; MMI 166; NEUTROPHIL COLLAGENASE; PRINOMASTAT; REBIMASTAT; RO 323555; SB 3CT; SMALL INTERFERING RNA; TANOMASTAT; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG; PROTEINASE INHIBITOR;

ADVANCED CANCER; ARTHROPATHY; BONE MARROW TRANSPLANTATION; CANCER; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CARCINOGENIC ACTIVITY; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG FATALITY; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; ENZYME SUBSTRATE; EXTRACELLULAR MATRIX; GENE MUTATION; GLIOBLASTOMA; HOMEOSTASIS; HUMAN; INFLAMMATORY DISEASE; LIVER METASTASIS; MULTIPLE MYELOMA; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; NONHUMAN; OSTEOARTHRITIS; PANCREAS CARCINOMA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SKIN CANCER; STOMACH CARCINOMA; VALIDATION PROCESS; CANCER INVASION; CELL TRANSFORMATION; CLASSIFICATION; DRUG ANTAGONISM; ENZYMOLOGY; FORECASTING; GENE EXPRESSION REGULATION; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY);

ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; EXTRACELLULAR MATRIX; FORECASTING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEASE INHIBITORS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 33644545381     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1821     Document Type: Review

References (110)

1. Drews, J. Drug discovery: a historical perspective. Science 287, 1960-1964 (2000).
2. Lindsay, M. A. Target discovery. Nature Rev. Drug Discov. 2, 831-838 (2003).
3. Williams, M. Target validation. Curr. Opin. Pharmacol. 3, 571-577 (2003).
4. López-Otín, C. & Overall, C. M. Protease degradomics: a new challenge for proteomics. Nature Rev. Mol. Cell Biol. 3, 509-519 (2002).
5. Puente, X. S., Sanchez, L. M., Overall, C. M. & López- Otín, C. Human and mouse proteases: a comparative genomic approach. Nature Rev. Genet. 4, 544-558 (2003).
6. Koopec, K. K., Bozyczko-Coyne, D. & Williams, M. Target identification and validation in drug discovery: the role of proteomics. Biochem. Pharmacol. 69, 1133-1139 (2005).
7. Liotta, L. A. et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284, 67-68 (1980).
8. Stetler-Stevenson, W. G. Progelatinase A activation during tumor cell invasion. Invasion Metastasis 14, 259-268 (1994).
9. Nagase, H. & Woessner, J. F. Matrix metalloproteinases. J. Biol. Chem. 274, 21491-21494 (1999).
10. Egeblad, M. & Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev. Cancer 2, 161-174 (2002).
11. Minn, A. J. et al. Genes that mediate breast cancer metastasis to lung. Nature 436, 518-524 (2005).
12. Minn, A. J. et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J. Clin. Invest. 115, 44-55 (2005).
13. Radisky, D. C. et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436, 123-127 (2005).
14. Weigelt, B., Peterse, J. L. & van't Veer, L. J. Breast cancer metastasis: markers and models. Nature Rev. Cancer 5, 591-602 (2005).
15. McCullagh, K., Wadsworth, H. & Hann, M. Carboxyalkyl peptide derivatives. European Patent EP126,974, 1-111 (1984).
16. Zucker, S., Cao, J. & Chen, W. T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19, 6642-6650 (2000).
17. Overall, C. M. & López-Otín, C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nature Rev. Cancer 2, 657-672 (2002).
18. Coussens, L. M., Fingleton, B. & Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392 (2002).
19. Fingleton, B. Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects. Expert Opin. Ther. Targets 7, 385-397 (2003).
20. Kumagai, K. et al. Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma. J. Immunol. 162, 4212-4219 (1999).
21. McCawley, L. J. & Matrisian, L. M. Matrix metalloproteinases: they're not just for matrix anymore! Curr. Opin. Cell Biol. 13, 534-540 (2001).
22. Aoki, T., Sumii, T., Mori, T., Wang, X. & Lo, E. H. Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke 33, 2711-2717 (2002).
23. Overall, C. M. Dilating the degradome: matrix metalloproteinase-2 cuts to the heart of the matter. Biochem. J. 383, E5-E7 (2004).
24. Parks, W. C., Wilson, C. L. & López-Boado, Y. S. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nature Rev. Immunol 4, 617-629 (2004).
25. Bergers, G., Javaherian, K., Lo, K. M., Folkman, J. & Hanahan, D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808-812 (1999).
26. Boehm, T., Folkman, J., Browder, T. & O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404-407 (1997).
27. McQuibban, G. A. et al. Matrix metalloproteinase activity inactivates the chemokine stromal-cell derived factor-1. J. Biol. Chem. 276, 43503-43508 (2001).
28. McQuibban, G. A. et al. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 100, 1160-1167 (2002).
29. Epstein, R. J. The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nature Rev. Cancer 4, 901-909 (2004).
30. Balkwill, F. Cancer and the chemokine network. Nature Rev. Cancer 4, 540-550 (2004).
31. Richardson, P. G. et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609-2617 (2003).
32. Overall, C. M. Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. Mol. Biotechnol. 22, 51-86 (2002).
33. Topol, E. J. Failing the public health - Rofecoxib, Merck, and the FDA. N. Engl. J. Med. 351, 1707-1709 (2004).
34. Psaty, B. M. & Furburg, C. D. COX-2 inhibitors - lessons in drug safety. N. Engl. J. Med. 352, 1133-1135 (2005).
35. Hopkins Tanne, J. Merck faces ongoing claims after Texan ruling on Rofecoxib. Br. Med. J. 331, 471 (2005).
36. Fidler, I. J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nature Rev. Cancer 3, 453-458 (2003).
37. Sodek, J. & Overall, C. M. in The Biological Mechanisms of Tooth Eruption and Root Resorption (ed. Davidovitch, Z.) 303-311 (EBSCO Media, Birmingham, 1988).
38. Engelholm, L. H. et al. uPARAP/Endo 180 is essential for cellular uptake of collagen and promotes fibroblast collagen adhesion. J. Cell Biol. 160, 1009-1015 (2003).
39. Curino, A. C. et al. Intracellular collagen degradation mediated by uPARAP/Endo 180 is a major pathway of extracellular matrix turnover during malignancy. J. Cell Biol. 169, 977-985 (2005).
40. Schenk, S. & Quaranta, V. Tales from the crypt[ic] sites of the extracellular matrix. Trends Cell Biol. 13, 366-375 (2003).
41. Pirila, E. et al. Matrix metalloproteinases process the laminin-5 γ2-chain and regulate epithelial cell migration. Biochem. Biophys. Res. Commun. 303, 1012-1017 (2003).
42. Handsley, M. M. & Edwards, D. R. Metalloproteinases and their inhibitors in tumor angiogenesis. Int. J. Cancer 115, 849-860 (2005).
43. O'Reilly, M. S., Holmgren, L., Chen, C. & Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med. 2, 689-692 (1996).
44. Tam, E. M., Morrison, C. J., Wu, Y. I., Stack, M. S. & Overall, C. M. Membrane protease proteomics: isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. Proc. Natl Acad. Sci. USA 101, 6917-6922 (2004).
45. Fingleton, B., Vargo-Gogola, T., Crawford, H. C. & Matrisian, L. M. Matrilysin (MMP-7) expression selects for cells with reduced sensitivity to apoptosis. Neoplasia 3, 459-468 (2001).
46. Balbin, M. et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nature Genet. 35, 252-257 (2003).
47. McQuibban, G. A. et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289, 1202-1206 (2000).
48. Fowlkes, J. L., Thrailkill, K. M., Serra, D. M., Suzuki, K. & Nagase, H. Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. Prog. Growth Factor Res. 6, 255-263 (1995).
49. Hemers, E. et al. Insulin-like growth factor binding protein-5 is a target of matrix metalloproteinase-7: implications for epithelial-mesenchymal signaling. Cancer Res. 65, 7363-7369 (2005).
50. Davies, N. M. & Jamali, F. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. J. Pharm. Pharm. Sci. 7, 332-336 (2004).
51. Khokha, R. et al. Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science 243, 947-950 (1989).
52. Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364 (1996).
53. Arbeit, J. M., Munger, K., Howley, P. M. & Hanahan, D. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J. Virol. 68, 4358-4368 (1994).
54. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002).
55. Ben-Baruch, A. Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res. 5, 31-36 (2003).
56. Ben-Baruch, A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin. Cancer Biol. 16, 38-52 (2006).
57. Brummelkamp, T. R., Bernards, R. & Agami, R. A system for stable expression of short interfering RNAs in mammalian cell. Science 296, 550-553 (2002).
58. Bramhall, S. R. et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br. J. Cancer 86, 1864-1870 (2002).
59. Bramhall, S. R. et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer 87, 161-167 (2002).
60. Groves, M. D. et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol. 20, 1383-1388 (2002).
61. King, J., Zhao, J., Clingan, P. & Morris, D. Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects. Anticancer Res. 23, 639-645 (2003).
62. van't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
63. Murray, G. I., Duncan, M. E., O'Neil, P., Melvin, W. T. & Fothergill, J. E. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nature Med. 2, 461-462 (1996).
64. Itoh, T. et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 58, 1048-1051 (1998).
65. Kruger, A. et al. Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res. 65, 3523-356 (2005).
66. Tester, A. M. et al. Pro-matrix metalloproteinase-2 transfection increases orthotopic primary growth and experimental metastasis of MDA-MB-231 human breast cancer cells in nude mice. Cancer Res. 64, 652-658 (2004).
67. Bergers, G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2, 737-744 (2000).
68. Davidson, B. et al. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression. Clin. Cancer Res. 10, 7335-7346 (2004).
69. Wilson, C. L., Heppner, K. J., Labosky, P. A., Hogan, B. L. & Matrisian, L. M. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl Acad. Sci. USA 94, 1402-1407 (1997).
70. Crawford, H. C., Scoggins, C. R., Washington, M. K. & Matrisian, L. M. Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancrease. J. Clin. Invest. 109, 1437-1344 (2002).
71. Wagenaar-Miller, R. A. et al. Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction. Br. J. Cancer 88, 1445-1452 (2003).
72. Montel, V. et al. Altered metastatic behavior of human breast cancer cells after experimental manipulation of matrix metalloproteinase 8 gene expression. Cancer Res. 64, 1687-1694 (2004).
73. Coussens, L. M., Tinkle, C. L., Hanahan, D. & Werb, Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481-490 (2000).
74. Witty, J. P., Lempka, T., Coffey, R. J. Jr & Matrisian, L. M. Decreased tumor formation in 7, 12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis. Cancer Res. 55, 1401-1406 (1995).
75. McCawley, L. J., Crawford, H. C., King, L. E. Jr, Mudgett, J. & Matrisian, L. M. A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res. 64, 6965-6972 (2004).
76. Gorrin Rivas, M. J. et al. Expression of human macrophage metalloelastase gene in hepatocellular carcinoma: correlation with angiostatin generation and its clinical significance. Hepatology 28, 986-993 (1998).
77. Yang, W. et al. Human macrophage metalloelastase gene expression in colorectal carcinoma and its clinicopathologic significance. Cancer 91, 1277-1283 (2001).
78. Overall, C. M. & Sodek, J. Concanavalin A produces a matrix degradative phenotype in human fibroblasts: induction and endogenous activation of collagenase, 72-kDa gelatinase, and Pump-1 is accompanied by the suppression of TIMP. J. Biol. Chem. 66, 1271-1281 (1990).
79. Holmbeck, K. et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99, 81-92 (1999).
80. Tam, E. M., Moore, T. R., Butler, G. S. & Overall, C. M. Characterization of the distinct collagen binding, helicase and cleavage mechanisms of matrix metalloproteinase 2 and 14 (gelatinase A and MT1-MMP): the differential roles of the MMP hemopexin C domains and the MMP-2 fibronectin type II modules in collagen triple helicase activities. J. Biol. Chem. 279, 43336-4344 (2004).
81. Overall, C. M. et al. Protease degradomics: mass spectrometry discovery of protease substrates and the CLIP-CHIP, a dedicated DNA microarray of all human proteases and inhibitors. Biol. Chem. 385, 493-504 (2004).
82. Kang, Y. et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549 (2003).
83. Muller, A. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (2001).
84. Nevo, I. et al. The tumor microenvironment: CXCR4 is associated with distinct protein expression patterns in neuroblastoma cells. Immunol. Lett. 92, 163-169 (2004).
85. Zhang, K. et al. Metalloproteinase cleavage of the chemokine SDF-1α induces neuronal apoptosis in HIV encephalitis. Nature Neurosci. 6, 1064-1071 (2003).
86. Neumark, E., Sagi-Assif, O., Shalmon, B., Ben-Baruch, A. & Witz, I. P. Progression of mouse mammary tumors: MCP-1-TNFα cross-regulatory pathway and clonal expression of promalignancy and antimalignancy factors. Int. J. Cancer 106, 879-886 (2003).
87. Basset, P. et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348, 699-704 (1990).
88. Boulay, A. et al. High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. Cancer Res. 61, 2189-2193 (2001).
89. Andarawewa, K. L. et al. Stromelysin-3 is a potent negative regulator of adipogenesis participating to cancer cell-adipocyte interaction/crosstalk at the tumor invasive front. Cancer Res. 65, 10862-10871 (2005).
90. Deng, H., Guo, R. F., Li, W. M., Zhao, M. & Lu, Y. Y. Matrix metalloproteinase 11 depletion inhibits cell proliferation in gastric cancer cells. Biochem. Biophys. Res. Commun. 326, 274-281 (2005).
91. Pendas, A. M. et al. Diet-induced obesity and reduced skin cancer susceptibility in matrix metalloproteinase 19-deficient mice. Mol. Cell Biol. 24, 5304-5313 (2004).
92. Kang, T. et al. Subcellular distribution and cytokine-and chemokine-regulated secretion of leukolysin/MT6-MMP/MMP-25 in neutrophils. J. Biol. Chem. 276, 21960-21968 (2001).
93. Gururajan, R., Grenet, J., Lahti, J. M. & Kidd, V. J. Isolation and characterization of two novel metalloproteinase genes linked to the Cdc2L locus on human chromosome 1p36.3. Genomics 52, 101-106 (1998).
94. Porter, S. et al. Dysregulated expression of adamalysin-thrombospondin genes in human breast carcinoma. Clin. Cancer Res. 10, 2429-2440 (2004).
95. Riddick, A. C. et al. Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br. J. Cancer 92, 2171-2180 (2005).
96. Greenbaum, D., Medzihradszky, K. F., Burlingame, A. & Bogyo, M. Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. Chem. Biol. 7, 569-581 (2000).
97. Abersold, R. & Mann, M. Mass spectrometry-based proteomics. Nature 422, 198-207 (2003).
98. De Leenheer, A. P. & Thienpont, L. M. Application of isotope dilution-mass spectrometry in clinical chemistry, pharmacokinetics, and toxicology. Mass Spectrom. Rev. 11, 249-307 (1992).
99. Gygi, S. P. et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nature Biotechnol. 17, 994-999 (1999).
100. Saghatelian, A., Jessani, N., Joseph, A., Humphrey, M. & Cravatt, B. F. Activity-based probes for the proteomic profiling of metalloproteases. Proc. Natl Acad. Sci. USA 101, 10000-10005 (2004).
101. Puerta, D. T. & Cohen, S. M. Examination of novel zinc-binding groups for use in matrix metalloproteinase inhibitors. Inorg. Chem. 42, 3423-3430 (2003).
102. Matziari, M., Beau, F., Cuniasse, P., Dive, V. & Yiotakis, A. Evaluation of P1′-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11. J. Med. Chem. 47, 325-336 (2004).
103. Cuniasse, P. et al. Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs. Biochimie 87, 393-402 (2005).
104. Bertini, I. et al. Conformational variability of matrix metalloproteinases: beyond a single 3D structure. Proc. Natl Acad. Sci. USA 102, 5334-5339 (2005).
105. Moy, F. J. et al. Impact of mobility on structure-based drug design for the MMPs. J. Am. Chem. Soc. 124, 12658-12659 (2002).
106. Morales, R. et al. Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12. J. Mol. Biol. 341, 1063-1076 (2004).
107. Dublanchet, A. C. et al. Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors. Bioorg. Med. Chem. Lett. 15, 3787-3790 (2005).
108. Lukacova, V. et al. Similarity of binding sites of human matrix metalloproteinases. J. Biol. Chem. 279, 14194-14200 (2004).
109. Butler, C. S. & Overall, C. M. Proteomic validation of protease drug targets. Pharmacoproteomics of matrix metalloproteinase inhibitor drugs using isotope-coded affinity tag labelling and tandem mass spectrometry. Curr. Pharm. Des. (in the press).
110. Overall, C. M. & Kleifeld, O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br. J. Cancer (in the press).